Logo image
TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome
Journal article   Peer reviewed

TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome

Agshin F Taghiyev, Natalya V Guseva, Rebecca A Glover, Oskar W Rokhlin and Michael B Cohen
Cancer biology & therapy, Vol.5(9), pp.1199-1205
09/01/2006
DOI: 10.4161/cbt.5.9.3168
PMID: 17110788

View Online

Abstract

The histone deacetylase inhibitor Trichostatin A (TSA) has previously been found to induce caspase activity in the human prostate cancer cell lines DU145 and LNCaP. TSA treatment resulted in the release of cytochrome c and Smac/DIABLO from mitochondria in DU145, and activation of caspase-9 in both cell lines. We concluded that TSA mediated its effect via the mitochondrial pathway. The aim of the current study was to determine how TSA initiated the caspase cascade. The results revealed that caspase-2 plays an important role in TSA-induced apoptosis. Inhibition of caspase-2 by siRNA or expression of caspase-2dn substantially decreased caspase activity after TSA treatment in both cell lines, siRNA caspase-2 also inhibited TSA-induced cell death. Caspase-2 acts upstream of caspase-8 and -9 and mediates mitochondrial cytochrome c release. Coimmunoprecipitation experiments show that caspase-2 formed protein complexes with RADD/RAIDD and PIDD. Together, these data indicate that caspase-2 initiates caspase cascade after TSA treatment and involves the formation of the PIDDosome.
Carrier Proteins - genetics Carrier Proteins - metabolism Caspase 2 - genetics Caspase 2 - metabolism Caspase 8 - metabolism Caspase 9 - metabolism Cell Death - drug effects Cell Line, Tumor CRADD Signaling Adaptor Protein - metabolism Cytochromes c - metabolism Death Domain Receptor Signaling Adaptor Proteins Enzyme Activation - drug effects Histone Deacetylase Inhibitors Humans Hydroxamic Acids - pharmacology Male Mitochondria - drug effects Mitochondria - metabolism Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology RNA, Small Interfering - genetics Transfection

Details

Logo image